<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  
    
  <dc:publisher>European Commission</dc:publisher>
    
  
    
  <dc:date>2026</dc:date>
    
  
    
  <dc:relation>isPartOf:https://phaidra.vetmeduni.ac.at/o:605</dc:relation>
    
  
    
  <dc:creator>Karolina Scahill</dc:creator>
    
  <dc:creator>Luis Pedro Carmo</dc:creator>
    
  <dc:creator>Ramazan Yildiz</dc:creator>
    
  <dc:creator>Mickael Cargnel</dc:creator>
    
  <dc:creator>Sébastien Buczinski</dc:creator>
    
  <dc:creator>Clair L Firth (Centre for Veterinary Public Health and One Health, Clinical Department for Farm Animals and Food System Transformation, Departments, University of Veterinary Medicine Vienna)</dc:creator>
    
  <dc:creator>Maria Stokstad</dc:creator>
    
  <dc:creator>Pierre-Louis Toutain</dc:creator>
    
  <dc:creator>Amelia R Woolums</dc:creator>
    
  <dc:creator>Lise Marie Ånestad</dc:creator>
    
  <dc:creator>Luca Guardabassi</dc:creator>
    
  <dc:creator>Bart Pardon</dc:creator>
    
  
    
  <dc:type xml:lang="eng">Text</dc:type>
    
  <dc:type xml:lang="eng">journal article</dc:type>
    
  
    
  <dc:source>issn:2732-5121</dc:source>
    
  
    
  <dc:rights>http://creativecommons.org/licenses/by/4.0/</dc:rights>
    
  
    
  <dc:format>application/pdf</dc:format>
    
  
    
  <dc:description xml:lang="eng">Background

Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used as ancillary therapy for bovine respiratory disease (BRD) alongside antimicrobials, and interest in NSAID monotherapy has grown amid antimicrobial stewardship and welfare concerns. We evaluated the clinical effectiveness of NSAIDs for BRD as adjunctive or sole therapy.

Methods

We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) in cattle with naturally occurring BRD. Databases searched were MEDLINE (Ovid), Embase (Ovid), CAB Abstracts (Ovid), Biological Abstracts (Ovid), Web of Science Core Collection, and Scopus (search: 22 Apr 2024; update: 12 Sep 2025). Primary outcomes were short-term treatment failure (need for re-treatment); secondary outcomes included relapse, mortality, adverse events, and performance where available. Random-effects pairwise meta-analyses estimated risk ratios (RRs) with 95% CIs. Risk of bias was assessed with a modified RoB 2.0 tool; certainty of evidence was appraised using GRADE. Registration/protocol: this review extends a prior ENOVAT BRD protocol; no separate registration was created. Funding: COST Action CA18217.

Results

Seventeen RCTs (22 comparisons; 4,909 animals) compared NSAID+antimicrobial versus antimicrobial alone. Adding an NSAID did not reduce re-treatment (RR 0.94, 95% CI 0.84–1.05; I2 = 0%; moderate certainty). Subgroup (same vs different antimicrobial) and sensitivity analyses (handling of multi-arm trials; follow-up restricted to ≤14 or ≤ 10 days; risk-of-bias restrictions) did not change conclusions. Two RCTs in UK dairy calves compared NSAID monotherapy with antimicrobial monotherapy (RR 1.19, 95% CI 0.72–1.97; very low certainty). Re-treatment is an indirect outcome and may not capture analgesia, fever reduction, or growth effects.

Conclusions

Across RCTs, NSAID use did not confer a clinically relevant reduction in re-treatment when added to antimicrobials, and evidence is very uncertain for NSAID monotherapy versus antimicrobials. Future trials should include validated pain/welfare measures, clinical and ultrasonographic outcomes, and performance metrics, with pathogen identification to explore effect modification.</dc:description>
    
  
    
  <dc:language>eng</dc:language>
    
  
    
  <dc:title xml:lang="eng">Efficacy of non-steroidal anti-inflammatory drug (NSAID) treatment for bovine respiratory disease: a systematic review and meta-analysis for the European Network for Optimization of Antimicrobial Therapy guidelines</dc:title>
    
  
    
  <dc:type xml:lang="ita">Documento PDF</dc:type>
    
  <dc:type xml:lang="ita">Articolo scientifico</dc:type>
    
  
    
  <dc:rights xml:lang="ita">Open Access</dc:rights>
    
  
    
  <dc:source xml:lang="eng">Open Research Europe</dc:source>
    
  
    
  <dc:rights xml:lang="eng">© 2026 Scahill K et al.</dc:rights>
    
  <dc:rights xml:lang="eng">open access</dc:rights>
    
  
    
  <dc:type xml:lang="deu">Text</dc:type>
    
  <dc:type xml:lang="deu">Wissenschaftlicher Artikel</dc:type>
    
  
    
  <dc:identifier>doi:10.12688/openreseurope.23174.2</dc:identifier>
    
  <dc:identifier>https://phaidra.vetmeduni.ac.at/o:5605</dc:identifier>
    
  
    
  <dc:subject xml:lang="eng">antimicrobial stewardship</dc:subject>
    
  <dc:subject xml:lang="eng">pneumonia</dc:subject>
    
  <dc:subject xml:lang="eng">calves</dc:subject>
    
  <dc:subject xml:lang="eng">inflammation</dc:subject>
    
  <dc:subject xml:lang="eng">animal welfare</dc:subject>
    
  
</oai_dc:dc>
